AstraZeneca (AZN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

AZN AstraZeneca

Watchlist

78.460
-0.500-0.63%

Trading Sep 13 10:16 ET

243.27BMarket Cap38.09P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | AstraZeneca And Daiichi Sankyo To Present Findings Of ENHERTU Showing Clinical Activity In Patients With HER2 Positive Metastatic Breast Cancer And Brain Metastases
Benzinga13minutes ago
ENHERTU (Fam-trastuzumab Deruxtecan-nxki) Showed Substantial Clinical Activity in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastases
Businesswire16minutes ago
AstraZeneca Stock Downgraded on Drug Trial Results
Schaeffer's Investment Research56minutes ago
Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More
Zacks 09:05 ET
AstraZeneca's Cancer Drug Trial Data Raises New Regulatory Concerns -- Market Talk
WSJ08:58 ET
'Moffitt Cancer Center Announces Strategic Collaboration With AstraZeneca To Accelerate Oncology Cell Therapies'
Benzinga08:53 ET

Comments

Movers and Shakers

1 hour ago

Columns Today's Morning Movers and Top Ratings | ADBE, ORCL, MRNA and More

Morning Movers
Gapping up
$Oracle (ORCL.US)$ Shares of Oracle surged over 6.2% as the company increased its revenue forecast for fiscal 2026 and provided strong guidance for the fiscal year 2029.
$Restoration Hardware (RH.US)$ Shares of the home furnishings retailer jumped 18.9% following a robust second quarter. RH reported adjusted earnings per share of $1.69 on revenue of $830 million, surpassing analysts' expectations of $1.56 p...

JovishehMY

Sep 5 09:22

Share Your Profit/Loss

frankinglily

Aug 25 22:03

Argument:
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...

Powell said it's time to cut: Will the market go wild?

Ryand83

Aug 10 16:18

$LumiraDx (LMDXF.US)$ I think whatever $ROCHE HOLDING AG (RHHBY.US)$ intends to do is going to be massive. Owning 75% or more of the company float means at the bare minimum if this were say a 50B deal Roche would only essentially lose out maximum 10B. I'm just thinking to myself if the other pharmas $AstraZeneca (AZN.US)$ & the other one got a piece of this 🥧 too.